News

Endpoints News5h
Il­lu­mi­na con­firms SEC has closed in­ves­ti­ga­tion in­to $8B Grail deal
Illumina on Thursday said the SEC has closed its investigation into the company's $8 billion purchase of Grail and doesn't ...
Endpoints News9h
AI-fo­cused biotech in­sitro cuts 22% of staff, cit­ing 'tu­mul­tuous mar­ket'
The AI-fo­cused biotech in­sitro has laid off 22% of its work­force, the com­pa­ny said in a Thurs­day state­ment. Found­ed ...
Endpoints News9h
As­traZeneca los­es ap­peals court fight over IRA drug price ne­go­ti­a­tions
AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...
Endpoints News10h
FDA grants Ve­rastem first ap­proval for rare ovar­i­an can­cer treat­ment
Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...
Endpoints News12h
Bris­tol My­er­s' $40B US in­vest­ment; Sh­iono­gi to buy Japan­ese drug­mak­er
BMS commits $40B for US expansion, Shionogi buys Torii Pharma for $1.05B, Bavarian Nordic extends BARDA deal, multiple ...
Endpoints News12h
Blood can­cer biotech Vor Bio ends clin­i­cal work, lays off 95% of staff
Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...
Endpoints News13h
'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis
Fyodor Urnov and Kiran Musunuru advocate for streamlined CRISPR treatments for rare genetic diseases, partnering with Danaher ...
Endpoints News15h
HAYA Ther­a­peu­tics gets $65M for 'dark genome' work fol­low­ing last year's Lil­ly pact
After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back ...